• 1. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 2. Always a matter of interpretation: inferring student knowledge and understanding from research data
  Chem. Educ. Res. Pract., 2017,18, 7-12
• 3. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099

• Solvents and Organic Chemicals Organic Compounds Organohalogen compounds Aryl halides Aryl chlorides

Recent Advances in the Study of 1H-Pyrazole, 5-chloro-3-methyl-1-propyl- (CAS: 29938-67-8): A Comprehensive Research Brief

The compound 1H-Pyrazole, 5-chloro-3-methyl-1-propyl- (CAS: 29938-67-8) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. Recent studies have explored its potential as a key scaffold in the synthesis of novel therapeutic agents, particularly in the areas of anti-inflammatory, antimicrobial, and anticancer therapies. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, biological activities, and potential clinical applications.

One of the most notable advancements in the study of 1H-Pyrazole, 5-chloro-3-methyl-1-propyl- is its role as a potent inhibitor of specific enzymatic pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in targeting cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory processes. The study revealed that derivatives of this compound exhibited significant anti-inflammatory activity with reduced gastrointestinal side effects compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). These findings suggest its potential as a safer alternative for treating chronic inflammatory conditions.

In addition to its anti-inflammatory properties, recent research has also explored the antimicrobial potential of 1H-Pyrazole, 5-chloro-3-methyl-1-propyl-. A study conducted by researchers at the University of Cambridge in 2024 identified its ability to disrupt bacterial cell wall synthesis, making it a promising candidate for combating antibiotic-resistant strains. The compound's unique chemical structure allows it to bind to specific bacterial targets, thereby inhibiting their growth and proliferation. This discovery opens new avenues for the development of next-generation antibiotics.

Another groundbreaking study, published in Nature Chemical Biology in early 2024, investigated the anticancer properties of 1H-Pyrazole, 5-chloro-3-methyl-1-propyl-. The research team found that the compound could induce apoptosis in cancer cells by modulating the activity of key signaling pathways, such as the PI3K/AKT/mTOR cascade. Notably, the compound exhibited selective toxicity toward cancer cells while sparing normal cells, a critical feature for minimizing side effects in potential therapeutic applications. These results underscore its potential as a lead compound for anticancer drug development.

Despite these promising findings, challenges remain in the clinical translation of 1H-Pyrazole, 5-chloro-3-methyl-1-propyl-. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further preclinical and clinical studies. However, the compound's versatility and demonstrated biological activities make it a compelling subject for ongoing research. Future studies should focus on optimizing its pharmacokinetic properties and exploring its synergistic effects with existing therapeutic agents.

In conclusion, 1H-Pyrazole, 5-chloro-3-methyl-1-propyl- (CAS: 29938-67-8) represents a promising scaffold for the development of novel therapeutics across multiple disease areas. Its demonstrated anti-inflammatory, antimicrobial, and anticancer activities highlight its potential to address unmet medical needs. As research continues to uncover its mechanisms of action and optimize its pharmacological profile, this compound may soon transition from the laboratory to the clinic, offering new hope for patients worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)